Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth...
-
Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4,...
-
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with...
-
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...
-
Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility$350 million initial term loan funded at close and up to an additional $150 million available...
-
• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a...
-
ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 ...
-
Jason Campagna, MD, PhD, rejoint Inventiva en tant que Président de la R&D et Directeur Médical, succédant à Pierre Broqua, PhD, et Michael Cooreman, MDMartine Zimmermann, PharmD, rejoint...
-
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice...
-
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved,...